Growth and differentiation potential of human bone marrow-derived mesenchymal stem cells in respons to dexamethasone and selection for collagen adherence by Weissman, Alexander Clemens
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2019
Growth and differentiation
potential of human bone
marrow-derived mesenchymal
stem cells in respons to
dexamethasone and selection for
collagen adherence
https://hdl.handle.net/2144/36728
Boston University
   
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
GROWTH AND DIFFERENTIATION POTENTIAL OF HUMAN BONE  
 
MARROW-DERIVED MESENCHYMAL STEM CELLS IN RESPONSE TO  
 
DEXAMETHASONE AND SELECTION FOR COLLAGEN ADHERENCE 
 
 
 
 
by 
 
 
 
 
ALEXANDER CLEMENS WEISSMAN 
 
B.S., Bates College, 2015 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of  
 
Master of Science 
 
2019  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 by 
 ALEXANDER CLEMENS WEISSMAN 
 All rights reserved   
   
Approved by 
 
 
 
 
First Reader   
 Louis C. Gerstenfeld, Ph.D. 
 Professor of Orthopaedic Surgery 
   
 
 
Second Reader   
 Paola Divieti Pajevic, M.D., Ph.D. 
 Associate Professor of Molecular and Cell Biology 
   
 
  iv 
ACKNOWLEDGMENTS 
 
I want to thank Dr. Louis Gerstenfeld, Dr. Paola Divieti Pajevic, Dr. Beth Bragdon, and 
Dr. Eric Smith for their guidance and support throughout my research and thesis project. I 
would also like to thank Jack Page, and Caroline Yu Liu for their help with experimental 
methods and technical support during my time in the lab. Finally, thank you to all my 
fellow students in the Gerstenfeld and Bragdon labs: Stephanie Diaz, Jessica Cashen, 
John Fernan, William Moore, Danielle Corbin, Katherine Sexton, and I-Ting Tsai. Best 
of luck to you all.  
  
  v 
GROWTH AND DIFFERENTIATION POTENTIAL OF HUMAN BONE 
MARROW-DERIVED MESENCHYMAL STEM CELLS IN RESPONSE TO 
DEXAMETHASONE AND SELECTION FOR COLLAGEN ADHERENCE 
ALEXANDER CLEMENS WEISSMAN 
ABSTRACT 
Osteoporosis (OP) is a chronic and progressive disease characterized by a 
decrease in bone mineral density (BMD), loss of bone tissue microstructure, and 
increased incidence of fracture. OP currently affects more than 10 million people in the 
United States, and its prevalence is expected to increase in the coming decades. This 
rising trend will add to the already $17 billion dollar per year healthcare industry which 
treats and rehabilitates those suffering from fragility related fractures. The causes of OP 
are multifactorial, with genetic and sex-dependent traits related to BMD and osteogenic 
cells having the largest effect on outcome.  
This study explored effective methods for culturing and inducing osteogenic 
differentiation in human bone marrow-derived mesenchymal stem cells (MSCs).  MSCs 
are multipotent progenitors cells, and of particular importance to the study of OP because 
of their contribution to bone and cartilage repair and regeneration throughout life. 
Specifically, our goals were to examine the relationships between osteoinductive medium 
containing dexamethasone (Dex) and collagen culture plate pretreatment on human bone 
marrow-derived MSC growth, differentiation, and mineralization. 
Bone marrow was obtained from the acetabular reamings of 10 patients (age 
range 51-68; sex: 6 female and 4 male) undergoing total hip arthroplasty. After isolation, 
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cells were cultured in a basal medium of Dulbecco’s Modified Eagle Medium with 10% 
fetal bovine serum and 10% penicillin/streptomycin. Plates were further designated as 
±collagen pretreatment, and +collagen plates were treated with a thin layer of collagen 
prior to cell seeding. On day 6 post seeding, the basal medium was replaced with an 
osteoinductive medium of α-Modified Eagle Medium, 10% fetal bovine serum, 1% 
penicillin/streptomycin, 12.5µg/mL ascorbic acid and 8mM β-Glycerophosphate. 
Osteogenic conditions were designated as ±10-8M Dex. After a 21 day culture in 
osteoinductive medium, cells were fixed and biochemical assays were assessed for DNA, 
alkaline phosphatase (ALP) and mineralization content. 
Plain photographic and phase-contrast microscopy examinations of cell cultures 
showed an increased tendency of +Dex cultures to promote earlier proliferation, and 
greater osteogenic nodule formation as quantified by alizarin red staining. There were no 
apparent qualitative differences in culture plates pretreated with collagen. Biochemical 
assays showed no significant difference in DNA content between either the -Dex or 
collagen conditions compared to the control (p>0.05). However, there was a significant 
difference in DNA content between patients (p<0.01). The addition of Dex had a 
significant effect on the DNA normalized ALP content of cell cultures (p<0.05). There 
was no significant difference in ALP content between groups with collagen pretreatment 
(p>0.05), or across patients for either the -Dex group or collagen group as compared to 
the control (p>0.05). Neither Dex as an osteoinductive component nor collagen coating 
tissue culture plates had a significant effect on mineralization as measured by DNA 
normalized alizarin red stain content (p>0.05). There was also no significant difference in 
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mineralization between patients for either the -Dex or collagen group as compared to the 
control (p>0.05).  
Our findings demonstrate the potential of Dex to induce in vitro MSC 
proliferation and differentiation, while cell culture plate pretreatment with collagen did 
not appear to have significant effects. Further study and larger sample sizes are needed to 
produce more statistically significant results and allow for examination of underlying 
patient genetics and co-morbidities.  
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INTRODUCTION 
 
1. Osteoporosis in the U.S.A. 
 
Osteoporosis (OP) is a widespread health concern in the United States, affecting 
approximately 10 million people (Kling, Clarke, & Sandhu, 2014). OP is a chronic 
disease characterized by a decrease in bone mineral density (BMD), loss of bone tissue 
microstructure, and increased incidence of fracture. OP is also a progressive disease, 
where bone quality continues to decline as an imbalance in bone resorption exceeds new 
bone production.  
In the United States, as is the case worldwide, the incidence of OP is expected to 
increase dramatically in the next few decades. One of the strongest indications of future 
OP in the U.S. population is the growing number of patients over the age of fifty. 
Between the years 2000 and 2025 it is projected that the population of those 50 and older 
will rise by more than 60% (Burge et al., 2007). These trends correlate to higher numbers 
of patients with OP as bone loss increases with age. Rates of OP increase in aging 
populations, with a 19% incidence in women aged 65-74 and greater than 50% incidence 
in women over 85 years old (Gass & Dawson-Hughes, 2006).  
These trends represent a high burden and cost on the American healthcare system 
that will continue to rise. The increased incidence of OP can be measured in both direct 
and indirect costs. The number of fragility fractures related to OP has increased to over 2 
million annually, at a cost of over $17 billion dollars. Beyond the monetary drain, large 
amounts of hospital and rehabilitation resources are delegated to OP related injury and 
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recovery (Budhia, Mikyas, Tang, & Badamgarav, 2012). By 2025 the number of OP 
related fractures in the U.S. are expected to exceed 3 million annually at a cost of over 
$25 billion dollars (Burge et al., 2007).  
Beyond financial costs, there are significant social costs associated with fragility 
related fractures. Of the approximately 300,000 annual hip fractures in the U.S. 
associated with OP, 10% result in death within six months (Harvey, Dennison, & Cooper, 
2010). While the incidence of OP is four times higher in women when compared to men 
(Budhia et al., 2012), the disease is not sex restricted. Men have mortality rates more than 
twice as high as women in the year following a hip fracture, 8% compared to 3% (Burge 
et al., 2007; Harvey et al., 2010). In addition to the mortality associated with OP, there is 
often a reduction in quality of life for those who survive a fragility related fracture, and 
many patients fail to return to normal daily functions. In the United States, as many as 
25% of patients become partially dependent on caregivers and 50% fail to walk 
independently after suffering a fragility related hip fracture (Harvey et al., 2010). 
With a globally aging population, research directed at better understanding the 
underlying mechanisms of OP and the loss of BMD can help offset future healthcare 
costs and help the growing number of patients affected with this progressive disease.  
 
2. Bone Density 
 
 OP is characterized by both the increased risk of fracture and decreased BMD 
associated with defects in bone microstructure. BMD is a sex-dependent, highly heritable 
trait, and low or declining BMD effects a large population in the United States. As many 
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as 40 million women in the U.S. are currently affected by low BMD (Figure 1), with the 
average Caucasian woman over 50 years of age having a 50% chance of fracture related 
to OP (Black & Rosen, 2016). Men however, are also susceptible to decreased BMD and 
experience bone loss with age. Reasons for higher female incidence of OP are 
multifactorial, including senile and postmenopausal bone loss, as well as developmental 
differences in bone geometry between men and women. Men tend to have higher bone 
density and larger bone geometry than women. This leads to thicker bone cortices and 
lower incidence of fracture even with OP and bone loss. With age, women tend to 
experience a greater loss in the number of trabecular spicules which may be due to 
postmenopausal hormonal changes, whereas men tend to experience trabecular thinning 
(Nieves, 2017).  
 Peak BMD has been shown to be as much as 85% heritable in twin and family 
studies with additional gene related contributions to age related bone loss (Liu et al., 
2012; Ralston, 2010). While BMD and bone microstructure have genetic components, it 
has become clear that effects of OP are under the control of a large number of genes with 
varying impact (Ralston, 2010).  
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Figure 1. Vertebrae of a Healthy 37 Year Old Male and a 75 Year Old Female 
Suffering from Osteoporosis. These two slides demonstrate the loss of bone density, 
decreased number of trabecular spicules and thinner cortices which result from 
osteoporosis (Turner Biomechanics, 2011).  
 
Many genes have been proposed and examined for their impact on BMD and therefore 
OP outcomes. Most of these genes affect bone remodeling through their effect on 
osteoblasts, osteoclasts, and osteocytes, as well as affecting calcium and collagen 
metabolism (Bonewald, 2011; Ralston, 2010). Genome-Wide Association Studies 
(GWAS) have given researchers the ability to compare entire study population genomes, 
and help identify specific loci and DNA variations associated with disease. GWAS have 
helped to isolate genomic regions associated with BMD by analyzing hundreds of 
thousands of single nucleotide polymorphisms (SNPs) instead of focusing on a single 
gene (Ralston, 2010; Richards, Zheng, & Spector, 2012). 
 
3. General Mechanisms and Treatment of Osteoporosis 
 
 OP which can be characterized by decreased BMD, changes in bone 
microstructure and increased risk for skeletal fractures, is highly prevalent in aging 
populations, most notably post-menopausal women (Black & Rosen, 2016). Additionally, 
OP has multiple underlying associations affected by age, sex, genetics and lifestyle. The 
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10 million Americans affected by OP have an increased risk for related fracture as well as 
high rates of associated morbidity and mortality (Sanders & Geraci, 2013).  
Unfortunately, OP is often undiagnosed and only recognized when patients suffer 
a fracture related to bone fragility (Pinkerton, Thomas, & Dalkin, 2013). Screening for 
OP is most frequently recommended for older women, and the National Osteoporosis 
Foundation suggests BMD testing for all women over 65 years of age or those who have 
sustained a fracture after the age of 50 (Sanders & Geraci, 2013). Screening for OP is 
most commonly done by dual-energy x-ray absorptiometry (DEXA) scans of the hip and 
lumbar spine to measure BMD. Patients are assigned T-scores (Table 1) to compare their 
BMD to a normal adult reference population, which helps clinicians in diagnosis and 
treatment (Black & Rosen, 2016; Gallagher & Tella, 2014; Gass & Dawson-Hughes, 
2006; Kerschan-Schindl, 2016).  
Table 1. Osteoporosis T-Score Evaluations. Clinical diagnosis of osteoporosis is often 
aided by bone densitometry scanning. T-Scores are assigned to represent bone mineral 
density values that are some standard deviation (SD) away from the reference population. 
Adapted from the World Health Organization diagnostic guidelines (Gallagher & Tella, 
2014; Gass & Dawson-Hughes, 2006). 
 
T-Score Bone Mineral Density  Diagnosis 
+2.5 to -1.0 Within 1 SD of an average young adult  Normal 
-1.0 to -2.5 1 to 2 SD below an average young adult Osteopenia 
Below -2.5 More than 2.5 SD below an average young adult Osteoporosis 
 
The pathophysiology of bone loss and the progression of OP can be better 
understood by examining the normal physiology of bone remodeling. Bone is not a static 
tissue, and is constantly broken down and remade by specialized cells. Osteoclasts, the 
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bone resorbing cells, are first recruited to the bone surface targeted for remodeling and 
create an acidic environment where mineral is liberated and the bone tissue is resorbed 
(Figure 2). Osteoblasts are then recruited to the resorption site and osteoclasts undergo a 
programed apoptotic death. Osteoblasts utilize the liberated mineral to deposit newly 
remodeled bone tissue (Gallagher & Tella, 2014; Tabatabaei-Malazy, Salari, Khashayar, 
& Larijani, 2017).  
In a normal physiological bone remodeling environment, the amount of new bone 
formed equals the bone resorbed. This coupling process occurs at a cellular level where 
osteoblasts and osteoclasts interact with direct cell-cell communication and through 
secreted factors (X. Chen et al., 2018). RANKL is an osteoblast produced cytokine either 
expressed as a transmembrane protein or secreted into the extracellular space, which 
binds to and activates the RANK protein found on the surface of osteoclast progenitor 
cells. This coupling mechanism requires sufficient osteoblast presence to activate 
osteoclast differentiation. As a further safeguard against bone remodeling imbalances, 
osteoprotegerin (OPG) produced by osteoblasts can bind to and disable RANKL, 
downregulating osteoclast activity (X. Chen et al., 2018; Sims & Martin, 2015). OP can 
occur when these normal processes are imbalanced and the amount of osteoclast 
resorption is greater than the corresponding osteoblast remodeling.  
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Figure 2. Bone Remodeling. Artist rendition of normal physiological bone remodeling. 
Osteoclasts are recruited to the bone surface where they resorb bone, liberating minerals. 
Osteoblasts then remodel the bone at the site of resorption utilizing the calcium rich 
environment. (UK, 2014). 
 
In addition to screening guidelines, preventative measures and non-
pharmaceutical lifestyle changes can reduce the associated risks of OP. Peak bone mass 
occurs from the age of 20-30 years old, and early prevention and lifestyle choices can 
have a dramatic effect on long term health and OP outcomes. Exercise has been shown to 
have a significant effect on increasing peak BMD in youth, and a 10% increase to peak 
BMD has been shown to reduce the risk for OP fracture by 50% (Kerschan-Schindl, 
2016). The most common dietary supplements suggested for those at risk for or 
diagnosed with OP, are calcium and vitamin D (Gallagher & Tella, 2014; Kerschan-
Schindl, 2016). However, there has been some disagreement about the effectiveness of 
these supplements for treating OP. A large study (n=36,000) of postmenopausal women 
conducted by the Women’s Health Initiative found that daily dietary supplementation 
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with 1000mg of calcium and 400IU of vitamin D had a non-significant effect on 
preventing fragility factors. Furthermore, women in the calcium cohort had a 17% higher 
risk of developing kidney stones. Regardless, the US National Osteoporosis Foundation 
suggests that those diagnosed with OP have a total daily intake of 1200mg calcium and 
800-1000IU vitamin D in addition to weight bearing exercise and potential 
pharmacologic intervention if warranted (Black & Rosen, 2016).  
Beyond dietary supplements, those at risk for OP are recommended to participate 
in daily weight bearing and balance exercises, as well as reducing alcohol and tobacco 
usage. Regular resistance training and weight bearing exercise increases overall BMD in 
patients at risk for OP, and develops flexibility and balance to prevent fracture inducing 
falls. Smoking has been shown to accelerate radial bone loss and has been associated 
with increased risk for fracture in OP patients (Gass & Dawson-Hughes, 2006; Pinkerton 
et al., 2013; Sanders & Geraci, 2013).  
For those OP patients who require further treatment to preserve BMD, 
pharmacological interventions are often warranted. OP medications are most commonly 
classified into two categories, either anti-resorptive or anabolic. Anabolic treatments 
work to increase BMD by stimulating osteoblasts to form new bone. Teriparatide is a 
recombinant form of parathyroid hormone (PTH) and was the first FDA approved 
anabolic OP treatment. Once daily injections of Teriparatide increase the rate and area of 
bone remodeling, suppress osteoblast apoptosis, and stimulate bone lining cells to 
become active osteoblasts, which leads to overall positive bone formation (Balani, Ono, 
& Kronenberg, 2017; Ma et al., 2006). Anti-resorptive medications are more commonly 
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prescribed, and target osteoclast activity to reduce excess bone resorption. 
Bisphosphonates (BPs) are a class of anti-resorptive medications which represent the 
most utilized pharmacological treatment for OP (Black & Rosen, 2016). BPs work 
through inactivating, and accelerating the apoptosis of osteoclasts to reduce bone 
resorption (Tabatabaei-Malazy et al., 2017). BPs are analogs of inorganic pyrophosphates 
and have a high affinity for hydroxyapatite, binding to the surface of bone in areas of 
active remodeling. In addition to preserving bone architecture, during resorption BPs 
promote osteoclast apoptosis through intracellular accumulation (Drake, Clarke, & 
Khosla, 2008; Gallagher & Tella, 2014; Gass & Dawson-Hughes, 2006).  
 Denosumab is another commonly prescribed anti-resorptive medication, and 
works as a monoclonal antibody, binding to and disabling RANKL proteins on 
osteoblasts which normally activate RANK proteins on osteoclast precursors (Figure 3). 
This mechanism is similar to naturally occurring OPG, which blocks RANKL and 
suppresses bone resorption (Gallagher & Tella, 2014; Pinkerton et al., 2013; Tabatabaei-
Malazy et al., 2017). Although there is a large body of knowledge to treat the currently 
understood mechanisms of OP, a better understanding of genetic factors and the 
precursor processes which facilitate BMD loss would help to better treat the millions 
affected by OP each year.  
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Figure 3. Mechanism of Denosumab to Neutralize RANKL on Osteoblasts. 
Denosumab is an anti-resorptive osteoporosis medication which mimics the action of 
osteoprotegerin (OPG). Through binding to and neutralizing RANKL, fewer osteoclast 
precursors will become active, and bone resorption is reduced (Levy, 2018).  
 
4. Mesenchymal Stem Cells  
 
Mesenchymal stem cells (MSCs) are a multipotent line of self-renewing non-
hematopoietic progenitor cells which are derived from bone marrow (Figure 4). These 
cells are defined by their ability to differentiate into osteoblasts, chondrocytes, and 
adipocytes which contribute to bone, cartilage, and fat respectively. Additionally, MSCs 
have been characterized in vitro by their ability to adhere to plastic (Baker, Boyette, & 
Tuan, 2015; Q. Chen et al., 2016; Ganguly et al., 2017). 
 
DENOSUMAB 
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Figure 4. Nodule of Mesenchymal Stem Cells in First Week of Growth Post Seeding. 
MSCs adherent to plastic substrate and beginning to form a cellular nodule. Cells were 
derived from the bone marrow of a patient consented in the study, and grown in a basal 
medium of DMEM, 10% FBS and 10% antibiotic.  
 
MSCs are of particular importance to the study of OP because of their 
contribution to the formation and remodeling of bone tissue. The regulation of bone 
formation and remodeling is a highly controlled process where bone forming cells, 
osteoblasts, are derived from MSCs and bone resorbing cells, osteoclasts, are derived 
from hematopoietic stem cells (Q. Chen et al., 2016). It is specifically the imbalance of 
these cells along with their progenitors which can result in bone diseases such as OP.   
Because the incidence of OP is positively correlated with increasing age (Harvey 
et al., 2010), there have been many studies to examine the relationship between MSC 
function and patient age. Overall, research has shown that the osteogenic potential of 
MSCs decrease as a person ages. This decline in osteoblastic forming potential leads to 
an imbalance in bone remodeling and possible osteopenia or OP (Ganguly et al., 2017). 
 12 
Another common finding is the increased shift of MSCs to differentiate towards 
adipocytes instead of osteoblasts as a person ages (Ganguly et al., 2017). This abnormal 
trend is further demonstrated by the higher bone marrow fat content that is observed in 
osteoporotic patients (Q. Chen et al., 2016). One of the proposed mechanisms of this shift 
between adipocyte and osteoblast is the genomic regulation of specific transcription 
factors. The upregulation of Runx2 in MSCs has been shown to promote differentiation 
into osteoblasts lineages, and inhibit adipocyte formation (Q. Chen et al., 2016). Beyond 
a shift in the osteogenic potential of aging MSCs, studies have shown a decrease in their 
bone marrow frequency in older populations, which may further contribute to the 
occurrence of OP (Baker et al., 2015). 
 
5. Ascorbic Acid and Collagen 
 
Ascorbic Acid (AA), or vitamin C is an organic compound needed as a co-factor 
in important biological processes. Unlike most mammals, humans and other primates are 
unable to synthesize their own AA. In the body, AA is oxidized to dehydroascorbate and 
eliminated through urine. Therefore, AA must be consumed as part of a normal diet to 
maintain key biological functions (D’Aniello, Cermola, Patriarca, & Minchiotti, 2017). 
AA is an important co-factor in the synthesis of collagen proteins. Collagens are the most 
abundant protein in humans and make up a majority of the extracellular matrix (ECM) 
and as much as 90% of bone mass (D’Aniello et al., 2017).  
On a biochemical level AA acts a co-factor for the lysyl hydrolase and prolyl 
hydrolase enzymes in the collagen synthesis mechanism. These enzymes catalase post 
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translational modifications of collagen proteins and are needed for the formation of the 
procollagen triple helix, secretion from the cell, and subsequent fibril aggregation (Figure 
5) (Boyera, Galey, & Bernard, 1998). Without adequate AA, these key hydrolase 
enzymes cannot function and collagen along with ECM production is affected.  
 
 
Figure 5. Formation of Collagen Fibers from Peptide Chains, by Successive 
Polymerizations. Artist interpretation of collagen fiber synthesis from individual chains 
to fibers. Ascorbic acid is used as a co-factor in collagen hydrolase reactions necessary 
for the triple helix and fibril formation and overall function of the protein (Solitchka, 
2005). 
 
AA has also been shown to be a key stimulator of mesenchymal derived cells, 
including chondrocytes, osteoblasts, and osteocytes. In cellular environments containing 
MSCs, AA stimulates the production of the ECM, encouraging growth and cellular 
differentiation. Additionally, the combination of AA with supplements such as β-
Glycerophosphate (βGP) has been shown to promote bone marrow-derived MSCs to 
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differentiate towards osteoblasts and encourage extracellular mineralization (D’Aniello et 
al., 2017).  
The importance of collagen and AA for the growth and differentiation of MSCs 
has encouraged studies examining the effects of artificially supplementing ECM proteins 
to promote in vitro cell cultures. Studies where human MSC culture plates were first 
coated in type I collagen found higher rates of proliferation, faster plate adherence and 
lower cell death than in control conditions (Somaiah et al., 2015). Other studies have 
examined the effect of supplementing in vitro human MSC growth with a mixture of 
ECM related proteins. Pretreating culture dishes with ECM components which contained 
collagen, had a significant effect on the proliferation and differentiation capacity for 
human bone marrow-derived MSCs (Lindner et al., 2010). In addition to common 
osteoinductive media additives, collagen pretreatments for culture plates have been 
shown to have a significant effect on MSC expansion and differentiation for in vitro 
studies.  
 
6. β-Glycerophosphate  
 
Inorganic phosphate plays an important role in promoting the osteogenic 
differentiation of MSCs. Without a suitable environment, and extracellular matrix with 
sufficient levels of phosphate, MSCs will not differentiate towards osteoblasts, or form 
bone. Phosphate induces ATP production, and promotes ECM mineralization through the 
paracrine and autocrine signaling of adenosine (Shih et al., 2014). Additionally, inorganic 
phosphate facilitates osteogenic differentiation through increased gene expression. 
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Phosphate has the ability to influence the MAP kinase signaling pathway through two 
independent phosphorylations of ERK which increases the expression of osteogenic 
proteins (Langenbach & Handschel, 2013).   
βGP is a common supplement added to the growth medium of MSCs to induce 
osteogenic differentiation. βGP can act as the source of phosphate needed for 
hydroxyapatite deposition, bone formation, and influence gene expression as previously 
mentioned. In trials where βGP was used as the source of inorganic phosphate in 
osteogenic medium to culture MSCs, those groups without βGP failed to mineralize 
(Orriss, Hajjawi, Huesa, MacRae, & Arnett, 2014). In MSCs, βGP is hydrolyzed by 
tissue non-specific alkaline phosphatase (TNAP) which becomes a source of inorganic 
phosphate for both mineral production and osteogenic differentiation (Orriss et al., 2014). 
It has also been shown that TNAP plays further roles in bone production by degrading 
inorganic pyrophosphate (PPi). PPi in the extracellular matrix acts to inhibit bone 
formation, but when degraded by TNAP, forms free inorganic phosphate to react with 
calcium and allow hydroxyapatite mineralization. Additionally, previous studies (Orimo 
& Shimada, 2008) have shown that βGP promotes TNAP gene expression in osteoblasts, 
enhancing the effect that βGP may have as an osteogenic additive in culture medium.  
 
7. Dexamethasone  
 
The chronic effects of prescribed glucocorticoid steroids are a reduction in BMD 
and the possible development of OP (Fan, Zhan, Li, Zhao, & Chen, 2015). Repeated 
usage of glucocorticoids disrupts the balance of bone remodeling by promoting the death 
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of osteoblasts and osteocytes, while upregulating osteoclast activity (Weinstein, 2012). 
Glucocorticoids are the largest secondary cause of OP and as many as 50% of patients 
undergoing long term steroid treatment will suffer a fragility related fracture (Weinstein, 
2012).  
Although glucocorticosteroids have a well-documented negative effect on patient 
bone density, they are a common additive for the osteogenic differentiation of MSCs in 
vitro. Most protocols for the growth and osteoinductive differentiation of human bone 
marrow-derived MSCs call for the addition of AA, βGP, and dexamethasone (Dex) a 
glucocorticosteroid (Langenbach & Handschel, 2013). Studies have shown that Dex is an 
essential component in osteoinductive medium, with +Dex conditions having 
significantly more ECM mineralization than controls (Jaiswal, Haynesworth, Caplan, & 
Bruder, 1997; Song, Caplan, & Dennis, 2009; Tangtrongsup & Kisiday, 2016). One 
proposed mechanism of Dex induced MSC osteogenesis is through increased expression 
of the MAP-Kinase pathway. The upregulation of MAPK-1 dephosphorylates and 
activates important transcription factors of Runx2, a gene partially responsible for 
osteogenic differentiation and mineralization. Furthermore, (Langenbach & Handschel, 
2013) suggests that Runx2 is needed for Dex induced osteogenesis and its absence in 
some in vitro experiments may be responsible for the varying results of adding Dex. 
Other studies have shown that low doses of Dex (<10-8M) have no significant effect on 
MSC osteogenic differentiation whereas high doses (>10-8M) will inhibit growth and 
promote MSC apoptosis through the activation of specific caspases (Fan et al., 2015). 
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While some discussion has been had to understand these different findings, many 
studies using glucocorticalsteroids in MSC growth medium are still at odds with one 
another. One attempt to resolve these results by (Jaiswal et al., 1997) was that Dex 
promotes MSC growth and differentiation significantly, to the point of depleting the 
upstream reserves of progenitor cells. However, others still hypothesize that any 
reduction of bone growth is due to an inhibitory steroid pathway.  
 
8. Study Goals 
 
This study examined the role of dexamethasone (Dex) and collagen along with 
ascorbic acid (AA) and β-Glycerophosphate (βGP) as osteoinductive additives in culture 
medium for human bone marrow-derived mesenchymal stem cells (MSC). The goal of 
this study was to determine if the addition of a glucocorticoid steroid in the form of Dex 
(10-8M) or culture well collagen pretreatment, resulted in greater MSC proliferation and 
osteogenic differentiation. While previous studies have concluded the positive effects of 
Dex as a MSC osteoinductive agent (Jaiswal et al., 1997), others have concluded that Dex 
has no effect at low doses (<10-8M)  and at high doses (>10-8M)  is a detriment to growth 
(Fan et al., 2015). Furthermore, the addition of a supplemental ECM pretreatment for cell 
culture wells has been shown to have a significant effect on MSC proliferation and 
differentiation (Lindner et al., 2010; Somaiah et al., 2015). Through manipulating the 
levels of Dex and collagen plate coatings, our lab measured the levels of ECM 
mineralization, alkaline phosphatase, and DNA produced by each condition as a 
determinant of differentiation, cell growth, and bone producing potential. By comparing 
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our results across diverse patient populations and to the current literature, we hoped to 
determine the most effective methods for culturing human bone marrow-derived MSCs 
and inducing osteogenesis.
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METHODS 
 
1. Acetabular Reaming Collection 
 
All human research was done under a Boston University School of Medicine 
Institutional Review Board Approved protocol: “Bone Tissues Repository”, IRB 
Number: H-35199. Acetabular reamings were collected from subjects (n=10; age range 
51-68; sex: 6 female and 4 male), undergoing total hip arthroplasty at Boston Medical 
Center from 2018-2019. Subjects were consented according to HIPAA guidelines prior to 
surgery, and given a copy of the consent form. Subject information was reviewed prior to 
participation and screened for exclusion criteria, including: chemotherapy treatment, 
sickle cell disease, rheumatoid arthritis, and OP medications known to modify bone 
metabolism. Subject clinical information was collected during normal pre-operative 
assessment (Table 2). After the surgical removal of acetabular reamings, the tissue was 
placed into a sterile container on ice and immediately transported to the lab for 
processing.  
Table 2. Study Subjects 
 
Subject # Sex Age BMI Blood Pressure Ethnicity 
203 F 59 29.87 124/85; 139/69 N/A 
204 F 60 22.27 96/65; 119/58 Caucasian 
205 F 51 27.27 134/80; 126/73 Caucasian 
206 M 58 23.2 137/87; 125/67 Caucasian 
207 F 61 29.57 137/88; 134/89 Caucasian 
208 M 64 26.21 135/80; 156/98 African American 
209 M 68 42.48 167/70; 159/74 Caucasian 
210 M 53 49.07 165/97; 155/73 Caucasian 
211 F 54 28.45 143/86 ; 103/59 Caucasian 
212 F 55 23.94 106/62 ; 102/59 African American 
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2. Cell Culture 
 
Bone marrow tissue samples were weighed before transfer to a laminar flow hood 
for further processing. Using sterile technique, acetabular reamings were washed with 
220ml Dulbecco’s Phosphate Buffered Saline (DPBS) (Sigma-Aldrich Corporation, St. 
Louis, MO), agitated and filtered using a stainless steel mesh screen to retain bone chips. 
The filtered cell solution was transferred to Falcon, 50mL sterile conical centrifuge tubes 
(Corning Inc., Corning, NY), and centrifuged at 1100rpm for 7 minutes. 5mL of fat was 
aspirated from each tube (Figure 6) to aid in filtering. Cell solution was further filtered 
through sterile 70 micron nylon cell strainers (Thermo Fisher Scientific, Waltham, MA) 
and 40 micron nylon cell strainers (Corning Inc., Corning, NY) to eliminate remaining 
bone chips or tissue. Cells were centrifuged at 1100rpm for 7 minutes, pellet suspended 
in 10mL DPBS and re-pelleted. Cells were counted using a hemocytometer and seeded 
on 24-well cell culture plates (Corning Inc., Corning, NY) in 750µL basal medium at a 
density of 2.66 x 106 cells per well for DNA, alkaline phosphatase and alizarin red 
concentration assays. For RNA assays, cells were seeded on 6-well cell culture plates 
(Corning Inc., Corning, NY) in 3mL basal medium at a density of 1.2 x 107 cells per well. 
 
 21 
 
Figure 6. Acetabular Cell Reaming Filtrate with Characteristic Fat Layer. After an 
initial filter through a stainless steel mesh strainer to retain bone chips, the acetabular cell 
solution was centrifuged to bring a majority of fat to the surface (arrow). By aspirating 
this top layer of fat, we were able to reduce the number of nylon filters used due to 
clogging, while maintaining a high yield of cells collected. 
 
Cells were seeded into animal component (FBS containing) (control) basal 
medium (Table 3). The control basal medium consisted of Dulbecco’s Modified Eagle 
Medium (DMEM) (Thermo Fisher Scientific, Waltham, MA) with 10% fetal bovine 
serum (FBS) (Atlanta Biologicals, Inc., Flowery Branch, GA) and 10% 
penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA). Control plates were 
further designated as ±collagen coating. +Collagen plates (CMCC) were coated with a 
thin layer of bovine dermal collagen (Cohesion Technologies Inc., Palo Alto, CA) and 
allowed to dry. Plates were then washed with DPBS before cell seeding. 
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Table 3. Animal Component Control Culture Conditions 
 
 Basal Culture Medium Osteoinductive Medium 
Media Base DMEM α-MEM 
Antibiotic 10% 1% 
FBS 10% 10% 
Osteoinductive 
Supplements 
N/A L- Ascorbic Acid 
(12.5µg/mL) 
  βGP (8mM) 
  ±Dex (10-8M) 
 
 
All cultures were maintained in a humidified incubator (37 °C, 5% CO2). Cells 
underwent a half basal medium change on day 4 post seeding and were given a full 
medium change on day 6 when they were switched to osteoinductive medium (Figure 7). 
Osteoinductive medium for the control condition consisted of α-Modified Eagle Medium 
(αMEM) (Thermo Fisher Scientific, Waltham, MA) with 10% FBS, 1% 
penicillin/streptomycin, ±10-8M Dex (Sigma-Aldrich Corporation, St. Louis, MO), 
12.5µg/mL AA (Sigma-Aldrich Corporation, St. Louis, MO), 8mM βGP (Sigma-Aldrich 
Corporation, St. Louis, MO). All plates were stored in a humidified incubator for 21 days 
with osteoinductive medium changed every 48 hours.  
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Figure 7. Cell Culture Timeline. Cells were plated in basal medium on the day of 
surgical collection from the patient. On day 4 after initial seeding, plates were given a 
half media change with basal medium. Starting on day 6, cells were placed in 
osteoinductive medium and given a full media change every 48 hours. Cells were fixed 
after 21 days in osteoinductive media, and prepared for biochemical assays. 
 
3. Cellular Repository Preparation 
 
Acetabular bone marrow cells from the primary experimental collection were 
frozen for addition to the project cell repository. Cells were preserved in a freezing 
solution of 90% Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich Corporation, St. Louis, 
MO), 10% FBS, and stored in cryogenic storage vials at a concentration of 20 million 
cells per mL. Frozen stock was initially cooled with a Thermo Scientific™ Mr. Frosty™ 
Freezing Container (Thermo Fisher Scientific, Waltham, MA) to achieve a cooling rate of 
-1°C/minute and maintain cell viability before -80°C long-term storage.  
 
4. Cell Culture Fixation  
4.1 Cell Culture Fixation for Alkaline Phosphatase and Alizarin Red Assays 
After aspirating osteoinductive medium from the 24-well plates at 28 days post 
seeding, cells were washed 3 times with DPBS. Cells were fixed in 500µL per well of 2% 
paraformaldehyde (PFA) for 30 minutes at room temperature. After fixation, cells were 
Day 
Plate 
Cells  
Half Basal 
Medium Change  
Change to 
Osteoinductive 
Medium  
Fix Cells for 
Assay 
01 04 06 28 
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washed with distilled water and refrigerated under distilled water at 4°C until 
quantification.  
4.2 Cell Culture Fixation for RNA Assay 
After aspirating osteoinductive medium from the 6-well plates at 28 days post 
seeding, cells were washed once with DPBS. RNA from each well was extracted with 
0.5mL Qiazol Lysis reagent (Sigma-Aldrich Corporation, St. Louis, MO) and 2 wells 
were combined into 1.5mL Eppendorf tubes, yielding 3 replicates per plate. Tubes were 
flash frozen with liquid nitrogen and stored at -80°C until RNA was prepared from the 
Qiazol reagent.  
4.3 Cell Culture Fixation for DNA Assay 
After aspirating osteoinductive medium from the 24-well plates at 28 days post 
seeding, cells were washed once using DPBS. Cell layers were then extracted using 
100µL per well of extraction buffer of 4M Guanidine HCl (Sigma-Aldrich Inc., Saint 
Louis, MO), 1% Triton X-100 Lysis Buffer (Sigma-Aldrich Inc., Saint Louis, MO), and 
10mM 1X TE Buffer (pH 7.4) (Life Technologies Inc., Beverly, MA). Extraction was 
carried out on a shaker plate for 30 minutes at room temperature. The extracted cell 
layers were then scraped from the surface using a sterile spatula and transferred to a 
1.5mL Eppendorf tube with an addition of 100μL Ultrapure Water (Thermo Fisher 
Scientific, Waltham, MA) per tube, and stored at -80° C until quantification. 
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5. Quantification of Biochemical Assays 
5.1 Quantification of Alkaline Phosphatase and Alizarin Red 
At the time of the assay, water was aspirated from 24-well plates and 450µL of 
ALP buffer was added to each well, in addition to 50µL of ALP substrate. ALP buffer 
consisted of 0.1M Glycine (Thermo Fisher Scientific, Waltham, MA) and 1nM 
Magnesium Chloride (Sigma-Aldrich Corporation, St. Louis, MO) at pH 10.5. ALP 
substrate consisted of p-nitrophenol phosphate disodium salt (EMD Millipore Corp., 
Burlington, MA), dissolved in distilled water at 20mg/ml. Plates were incubated for 30 
minutes at room temperature and covered with aluminum foil to shield from light. 500µL 
of the activated ALP solution was transferred to 1.5mL Eppendorf tubes with 500µL 
0.2N NaOH to neutralize. 100µL of each neutralized sample was aliquoted to 96-well 
clear bottomed microplates and optical density (OD) was measured at an absorbance of 
405nm on a BioTek Synergy 2 Multi-mode Microplate Reader. Remaining ALP solution 
was removed from each well and plates were washed with distilled water, and stored at 
4°C for alizarin red quantification.  
Water was aspirated from 24-well plate and 450µL of 2% alizarin red solution 
(Thermo Fisher Scientific, Waltham, MA) was added to each well for a 30 minutes 
incubation at room temperature. Alizarin red solution was removed and cells were 
washed with distilled water 4 times, agitating on a shaker plate for 5 minutes between 
washes. Distilled water was added to plates to prevent cells from drying, and photographs 
were taken to record the presence of mineralized nodules. Water was aspirated and 
200µL of 10% acetic acid (American Bioanalytical, Natick, MA) was added to each of 
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the 24 wells for a 30 minute incubation with shaking. Wells were scraped to loosen cells 
and culture plates were heated on a hotplate for 10 minutes at 85°C. Plates were then 
transferred to ice for 5 minutes to reduce evaporation. Cells and acetic acid from each 
well were transferred to 1.5mL Eppendorf tubes and centrifuged at 14,000 rpm for 20 
minutes. 175µL of supernatant was transferred to a new 1.5mL Eppendorf tube and 
neutralized with 66µL 10% ammonium hydroxide (Sigma-Aldrich Corporation, St. 
Louis, MO). 100µL of each neutralized sample was aliquoted into 96-well clear bottomed 
microplates and OD was measured at an absorbance of 405nm on a BioTek Synergy 2 
Multi-mode Microplate Reader. 
5.2 Quantification of DNA 
After thawing frozen samples at room temperature, DNA was quantified using a 
Quant-iT™ PicoGreen ® assay kit (Thermo Fisher Scientific, Waltham, MA). 50µl of 
each sample was diluted 1:1 in 1X TE buffer and added to an opaque 96-well microplate. 
100µl of PicoGreen reagent was added to each well per the manufacture protocol and the 
plates were shielded from light and placed on a shaker table for 2 minutes. Plates were 
read for fluorescence on a BioTek Synergy 2 Multi-mode Microplate Reader with an 
excitation and emission profile of 485/20 and 530/25 respectively.  
 
6. Statistical Analysis 
 
Mean values for each treatment and biochemical assay were calculated from 
individual standardized fluorescence and absorbance measurements. Additionally, 
standardized values for alizarin red and alkaline phosphatase were normalized to DNA 
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content to provide a more representative value of osteogenic potential per cell.  Results 
were compared between the different study conditions and across patients using a two-
factor repeated measures analyses of variance (ANOVA) to determine differences due to 
the addition of Dex to the osteoinductive medium, and collagen as a culture well pre-
treatment at a significance of α = 0.05. 
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RESULTS 
 
1. Cell Culture Growth and Osteogenesis  
 
Both plain photographic and phase-contrast microscopy examinations of sample 
human bone marrow-derived MSC cultures were used to explore differences in cell 
growth and differentiation between experimental conditions. Cells that were cultured in 
osteoinductive medium containing Dex (10-8M) showed a higher tendency to form 
osteogenic nodules as quantified by alizarin red staining (Figure 9). Both ±Dex 
conditions achieved full confluence before fixation, but +Dex cultures appeared to form 
cellular nodules earlier and proliferate more quickly (Figure 8). There were no apparent 
differences in cultures where plates were pretreated with a collagen coating.  
 
 
 
Figure 8. Cell Culture Proliferation with Dexamethasone. Cell culture morphology at 
days 6, 7 and 14 post plating, captured with a phase-contrast microscope. The top row 
shows cells cultured in osteoinductive media containing Dex (10-8M). The bottom row 
shows the same cell line cultured in osteoinductive media without Dex. 
6 7 
 
14 
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Figure 9. Alizarin Red Staining of Sample #211 Control and Control -Dex. 
Representative example of osteogenic nodule formation at 21 days post transition to 
osteoinductive medium. After alizarin red staining of sample #211, the bottom wells 
(CM) show a distinct coloration indicative of mineralization, while the top wells (CM-
Dex) lack coloration.  
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Figure 10. Cell Culture Sample #209 Showing Cell Confluence With and Without 
Osteogenesis. Cell culture morphology captured with a phase-contrast microscope at 40x 
magnification. Both images show the same culture well after 21 days in osteoinductive 
medium and staining with alizarin red. The bottom image shows a typical osteogenic 
nodule where the top image shows cells which did not mineralize.  
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2. DNA Content Quantification 
 
The DNA content of cell cultures was measured with a PicoGreen fluorescence 
assay (Figures 11+12). Fluorescence values were standardized to a curve of known DNA 
concentrations and averaged across duplicate wells and patients. There was no significant 
difference in the amount of DNA in groups where the osteogenic growth medium 
included Dex (10-8M) (p>0.05). There was also no significant difference in the amount of 
DNA between groups where the osteogenic medium included a collagen coated plate 
(p>0.05). Across patients there was a significant difference in the amount DNA content 
for both the –Dex group and collagen coated group as compared to the control (p<0.01).  
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Figure 11. DNA Concentration and Total Averages of Groups in ±Dex Animal 
Component Medium Conditions. DNA concentration was quantified using a PicoGreen 
fluorescence assay. There was no significant difference in the content of DNA between 
groups in the ±Dex osteoinductive conditions, but there was a significant difference 
across patients. Fluorescence values from the excitation/emission at 485nm/530nm for 
each condition were normalized to a standard curve of known DNA concentration.  
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Figure 12. DNA Concentration and Total Averages of Groups in CM/CMCC 
Animal Component Medium Conditions. DNA concentration was quantified using a 
PicoGreen fluorescence assay. There was no significant difference in the content of DNA 
between groups in the CM/CMCC culture conditions, but there was a significant 
difference across patients. Fluorescence values from the excitation/emission at 
485nm/530nm for each condition were normalized to a standard curve of known DNA 
concentration.  
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3. Alkaline Phosphatase Content Quantification  
 
The ALP content of cell cultures was determined using a p-nitrophenol phosphate 
disodium salt substrate, colorimetric absorbance measurement (Figures 13+14). 
Absorbance values were standardized to a curve of known ALP concentrations, 
normalized to sample DNA content, and averaged across duplicate wells and patients. 
Groups where the osteogenic growth medium included Dex (10-8M), had a significantly 
higher level of ALP than those without Dex (p<0.05). There was no significant difference 
in the amount of ALP between groups where the osteogenic medium included a collagen 
coated plate (p>0.05). Across patients there was no significant difference in the ALP 
content for either the –Dex group or collagen coated group as compared to the control 
(p>0.05). 
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Figure 13. Alkaline Phosphatase Concentration and Total Averages of Groups in 
±Dex Animal Component Medium Conditions. ALP was quantified using a 
colorimetric p-nitrophenyl phosphate substrate absorbance assay. There was a significant 
difference in the content of ALP between groups in the ±Dex osteoinductive conditions, 
but no significant difference across patients. Values from the absorbance reading at 
405nm for each condition were standardized to a known ALP curve and normalized to 
sample DNA content.  
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Figure 14. Alkaline Phosphatase Concentration and Total Averages of Groups in 
CM/CMCC Animal Component Medium Conditions. ALP concentration was 
quantified using a colorimetric p-nitrophenyl phosphate substrate absorbance assay. 
There was no significant difference in the content of ALP between groups or across 
patients in the CM/CMCC culture conditions. Values from the absorbance reading at 
405nm for each condition were standardized to a known ALP curve and normalized to 
sample DNA content.  
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4. Calcium Content Quantification  
 
The ECM mineralization of cultures was determined using an alizarin red 
colorimetric absorbance measurement (Figure 15+16). Absorbance values were 
standardized to a control blank, normalized to sample DNA content, and averaged across 
duplicate wells and patients. Groups where the osteogenic growth medium included Dex 
(10-8M) did not have a significantly different level of alizarin red stain than those without 
Dex (p>0.05). There was no significant difference in the amount of alizarin red stain 
between groups where the osteogenic medium included a collagen coated plate (p>0.05). 
Across patients there was no significant difference in the amount alizarin red stain 
content for either the –Dex group or collagen coated group as compared to the control 
(p>0.05). 
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Figure 15. Calcium Concentration and Total Averages of Groups in ±Dex Animal 
Component Medium Conditions. Mineralization was quantified using an alizarin red 
colorimetric absorbance assay. There was no significant difference in the content of 
alizarin red stain between groups or across patients in the ±Dex osteoinductive 
conditions. Values from the absorbance reading at 405nm for each condition were 
standardized to a control blank and normalized to sample DNA content.  
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Figure 16. Calcium Concentration and Total Averages of Groups in CM/CMCC 
Animal Component Medium Conditions. Mineralization was quantified using an 
alizarin red colorimetric absorbance assay. There was no significant difference in the 
content of alizarin red stain between groups or across patients in the CM/CMCC culture 
conditions. Values from the absorbance reading at 405nm for each condition were 
standardized to a control blank and normalized to sample DNA content.  
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DISCUSSION 
 
 This study examined the relationships between osteoinductive medium containing 
Dex and culture plate collagen pretreatment on human bone marrow-derived MSC 
growth, differentiation, and mineralization. The goals of this study were to determine the 
most effective way for growing human bone marrow-derived MSCs and to examine 
whether Dex or collagen coating tissue culture plates affected osteogenic differentiation. 
These goals were carried out by culturing MSCs from acetabular reamings of patients 
undergoing total hip arthroplasty, in different mediums containing ±Dex (10-8M) or 
±collagen coated culture plates and quantifying the content of DNA, alkaline 
phosphatase, and ECM mineralization. 
 
1. Dexamethasone  
1.1 DNA 
Over the 21 day osteoinductive cell culture, fibroblast like cells continued to 
attach to the plastic culture wells, form nodules, and divide until reaching confluence. 
Measuring the total DNA content of each culture well helped to determine the cellular 
content of the plate and to further normalize biochemical assays. Our study used replicate 
culture plates to grow cells for DNA assay. This procedure allowed us to easily separate 
and run assays for alizarin red, ALP and DNA. However, by having the DNA content 
measured from replicate wells we made the assumption that total DNA was equal across 
culture plates. Future studies may attempt to run DNA content assays in the same cell 
culture well after obtaining other biochemical assays of interest.  
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Cells that were cultured in osteoinductive media without Dex had no significant 
difference in DNA content than cells cultured in the control osteoinductive medium. 
These findings suggest that the addition of Dex at a concentration of 10-8M did not have a 
significant effect on cell growth over the 21 day osteoinductive culture. These results are 
consistent with Fan, 2015 who found that low doses of Dex (<10-8M) had no effect on the 
proliferation of MSCs (Fan et al., 2015).  
There was a highly significant difference in DNA content measured between 
patients. The differences in DNA between patients explain our qualitative assessments of 
cell cultures and the wide range of cell growth in different patient groups. These results 
highlight the variability in human studies over animal models, and hint to various 
potential genetic differences and co-morbidities which affected overall cell growth in our 
study. A greater number of patients beyond these initial 10 will help to further uncover 
trends and provide a more normal distribution for statistical analysis.  
1.2 Alkaline Phosphatase, Alizarin Red, and Osteogenesis 
 
After cells were switched into osteoinductive medium on day 6 post seeding, 
MSCs began the process of differentiating towards osteoblasts. The measurement of ALP 
and alizarin red staining normalized to DNA content allowed us to examine the 
differences between growth mediums in relation to the formation of a mineralized ECM.  
ALP levels normalized to DNA content were significantly affected by 
osteoinductive culture medium containing Dex. As MSCs differentiate towards 
osteoblasts,  rising ALP content hydrolyzes βGP to increase the availability of inorganic 
phosphate needed for hydroxyapatite production (Orimo & Shimada, 2008). Increased 
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levels of ALP suggest more active early stages of osteogenesis and differentiation of 
MSCs. These findings are in line with previous studies, that suggest Dex as an essential 
component of MSC osteoinductive medium along with AA and βGP (Jaiswal et al., 
1997). ALP levels normalized to DNA content were not significantly different between 
patients. This result shows a uniform capability of patient MSCs to undergo 
differentiation and produce ALP as part of osteogenesis.  
The content of cellular alizarin red staining as an indication of osteoblast 
hydroxyapatite production was not significantly affected by Dex as a component of 
osteoinductive medium. This finding goes against the majority of studies which have 
shown Dex as an essential component of MSC osteoinductive medium. The qualitative 
data, and images of osteogenic nodules after alizarin red staining (Figure 10) suggest a 
significant difference which our data may have been approaching. The statistical analysis 
of alizarin red content was hindered by a small sample size and the high variance 
between patients. Additionally, we did not find an increase of Dex induced apoptosis as 
(Fan et al., 2015) suggests, as the DNA content between study conditions was not 
significantly different. Alizarin red staining content normalized to DNA was not 
significantly different across patients. Although alizarin red content was not significantly 
different between study conditions, this result shows a uniform ability for cells to 
undergo differentiation and mineralize the extracellular environment.  
There were significant differences in DNA content between patients with 
insignificant differences in the DNA normalized values for ALP and alizarin red stain 
content. This suggests that while different patients had high variability in cell growth, the 
 43 
content of osteogenic markers produced per cell were not significantly different between 
patients. While patients had highly significant differences in cell proliferation, each cell 
across patients was not significantly different in its propensity for osteogenesis and the 
production of hydroxyapatite mineralized ECM.  
 
2. Collagen 
 
There was no significant difference in DNA content, alkaline phosphatase content 
or mineralization of MSCs grown in culture wells pretreated with a collagen coating. 
MSCs growth and differentiation towards osteoblasts is aided by a rich ECM containing 
collagen (D’Aniello et al., 2017). Our initial interests in this condition were that coating 
the wells in collagen may have provided cells with an earlier favorable growth and 
osteogenic environment. However, the initial biochemical assays and qualitative 
examination of cell growth showed no significant difference in cells cultured with 
collagen. These results are in contrast to studies where artificial supplementation of the 
ECM in the form of plate treatments had a significant effect on bone marrow-derived 
MSC attachment, proliferation and differentiation potential (Lindner et al., 2010; 
Somaiah et al., 2015). Collagen pretreatment was stopped after 6 patients to reduce costs 
and refocus efforts on other potential growth conditions. Further studies with a larger 
sample size may have different results with a stronger statistical basis for determining 
significance.  
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3. Limitations  
 
This study had several limitations, which affected statistical significance and 
overall outcome. The small sample size of the study combined with large variations in 
patient cell growth hindered our ability to assess the role of Dex as a component in MSC 
osteoinductive culture medium, or collagen as a culture well pretreatment.  
The protocols for biochemical assays could be improved to increase efficiency 
and result in more consistency for time sensitive colorimetric incubations.  Most cells for 
our biochemical assays were grown in 24-well culture plates with as many as 4 growth 
conditions per patient. The large number of duplicates and individual replicate samples 
often led to extended pipetting times and colorimetric incubation differences between the 
first and last sample. This may have contributed to human error and affected the variance 
between replicates.  
Cells used for DNA content assays were grown in separate replicate wells from 
those used to determine alizarin red and alkaline phosphatase content. This protocol 
assumed that the DNA content was homogenous between wells with the same patient and 
culture condition. Future studies may attempt to assay DNA content directly from the 
wells used for previous biochemical assays to obtain more accurate normalized results.  
Another potential issue with methods that may have affected outcomes, was the 
seeding of culture plates. MSCs were plated from an aliquot of DPBS and filtered bone 
marrow cell solution. The cellular majority of this solution were red blood cells, and as 
few as 0.0017% of cells obtained from bone marrow samples may actually be MSCs 
(Alvarez-Viejo et al., 2013). Because cells were plated based on total cell count there is a 
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possibility of variation in the number of MSCs plated in each well. These variations 
would be even more pronounced in the 24-well dishes where only 2.66 million cells in 
total were plated per well. In further studies, this issue may be solved using methods 
described by (Horn et al., 2008), where whole marrow is first subjected to a Ficoll-Paque 
and red blood cell lysis treatment to more accurately isolate and count MSCs for plating.  
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CONCLUSION 
 
This study examined the role of collagen plate pretreatments and Dex as osteoinductive 
components in culturing human bone marrow-derived MSCs. While our findings 
demonstrate the potential of Dex to induce in vitro MSC proliferation, differentiation, and 
mineralization of the ECM, further study and larger sample sizes are needed to produce 
more significant results. We determined that a culture plate pretreatment with collagen 
did not have a significant effect on MSC growth or osteogenesis. Our study expands on 
the current literature surrounding in vitro MSC culture technique, in demonstrating the 
effects of Dex and collagen on MSC proliferation and differentiation. The results from 
the initial 10 patients used in our study lay the foundation for cell culture methods and 
osteoinductive components to be used in future work. Better understanding the 
underlying genetics and co-morbidities associated with BMD and OP will help improve 
future research, treatment options, and patient outcomes.  
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